Oss, March, 27th, 2017 – NTRC will exhibit its services at the AACR conference 2017, to be held in Washington D.C. next week. Please be welcome at booth #3050 in the Exhibition Hall.
Two posters on the TTK kinase drug discovery program will be presented on Tuesday, April 4th.
Poster Titles and Sessions:
Title: Stable aneuploid cells are more sensitive to TTK inhibition than chromosome instable cell lines
Session Title: Mitosis, Telomeres, and Proliferation Control Session
Date & time: Tuesday April 4th, 8:00 am – 12:00pm
Location: Poster Section #19, Poster Board #7, Poster #3457
Presenter: Marion Libouban
Title: NTRC 1501-0, a TTK kinase inhibitor selected for its long target residence time, completely inhibits tumor growth in the MDA-MB-231 xenograft model for triple-negative breast cancer
Session Title: Targeting Protein Kinases and DNA Repair
Date & time: Tuesday April 4th, 1:00 – 5:00pm
Location: Poster Section #7, Poster Board #8, Poster #4185
Presenter: Joost Uitdehaag
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, and SynergyFinder™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NFK GreenScreen™, an assay read-out for the cancer immunotherapy drug targets IDO1 and TDO, is supplied to clients globally. For more information please visit www.ntrc.nl or contact email@example.com